Update, Amgen faces Delaware patent verdict, shares under legal scrutiny

Updated at 07:04. Amgen faces a Delaware jury verdict on antibody patent infringement, with damages of more than 20 million US dollars reported by analyst commentary based on court filings.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 07:04.

Update 1. Previous article at 07:04.

Amgen (US0311621009) is back on the NASDAQ after a Delaware federal jury found willful infringement of an antibody patent owned by Harbour BioMed and awarded more than 20 million US dollars in damages, according to analyst commentary based on court filings and market data. Ad hoc news report on the verdict

Delaware verdict details

The Yahoo Finance analysis cited in the report says the jury in June 2026 found Amgen and a subsidiary had willfully infringed Harbour BioMed’s Grosveld patent. It cites damages of 20,203,704 US dollars and notes that US law can allow enhanced damages in willful cases. Yahoo Finance analysis

The same market report places Amgen on the NASDAQ and lists the ticker AMGN, while Marketscreener shows trading activity on 2026-06-22 at 344.72 US dollars with 2,520,964 shares traded. That gives the ruling an immediate market context on Tuesday, June 23, 2026. Marketscreener quote and trading data

Analysts and peers

MarketBeat’s Amgen news page and the Marketscreener consensus feed both keep the stock inside a broad Wall Street coverage set, with research summaries clustering around a Buy or Overweight stance. The legal case now adds a fresh line item for analysts watching antibody platforms and intellectual property exposure. MarketBeat Amgen news page

Amgen’s antibody platform

Amgen’s business centers on biologic medicines, with antibody programs and marketed therapies such as Enbrel, Otezla, and Tezspire forming part of the company’s commercial base. The patent dispute lands directly in that core research-and-development model.

Amgen on NASDAQ

The Amgen shares (US0311621009) trade on 2026-06-22, 22:00 on NASDAQ at 344.72 US dollars.

Amgen at a glance

• Company: Amgen Inc.
• ISIN: US0311621009
• WKN: 867900
• Ticker: AMGN
• Trading venue: NASDAQ
• Price (as of 2026-06-22, 22:00): 344.72 USD
• Market cap: 182B USD (as of 2026-06-22)
• Sector / industry: Biopharmaceuticals
• Next earnings date: not officially scheduled

Disclaimer: This article is for information only and is not investment advice.